摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

epibatidine | 162599-17-9

中文名称
——
中文别名
——
英文名称
epibatidine
英文别名
2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
epibatidine化学式
CAS
162599-17-9
化学式
C11H13ClN2
mdl
——
分子量
208.691
InChiKey
NLPRAJRHRHZCQQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

ADMET

毒理性
  • 毒性总结
Epibatidine 通过与烟碱型乙酰胆碱受体结合并激活它们起作用。
Epibatidine works by binding and activating nicotinic acetylcholine receptors. (L1074)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 致癌物分类
对人类无致癌性(未列入国际癌症研究机构IARC清单)。
No indication of carcinogenicity to humans (not listed by IARC).
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 健康影响
Epibatidine 是一种神经毒性的物质。它还可能在神经肌肉接头处引起受体阻断,导致呼吸麻痹和死亡。它也是一种强效的镇痛剂。
Epibatidine is neurotoxic. It may also cause receptor blocks at neuromuscular junctions, causing respiratory paralysis and death. It is also a powerful analgesic. (L1074)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 暴露途径
注射(刺伤/咬伤)(A2835);吸入(吸烟)(L1810)
Injection (sting/bite) (A2835) ; inhalation (smoking) (L1810)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 症状
Epibatidine 是一种神经毒性的物质。它还可能在神经肌肉接头处引起受体阻断,导致呼吸麻痹和死亡。它也是一种强效的镇痛剂。
Epibatidine is neurotoxic. It may also cause receptor blocks at neuromuscular junctions, causing respiratory paralysis and death. It is also a powerful analgesic. (L1074)
来源:Toxin and Toxin Target Database (T3DB)

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    二碳酸二叔丁酯epibatidine三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 7.0h, 以89%的产率得到2-(6-Chloro-pyridin-3-yl)-7-aza-bicyclo[2.2.1]heptane-7-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    [3 + 2]非稳定的甲亚胺叶立德的环加成。7. Epibatidine及其类似物的立体选择性合成。
    摘要:
    Epibatidine(1)是通过将非稳定的偶氮甲叶立德10用作关键步骤,采用[3 + 2]环加成策略合成的,该不稳定基是由N-苄基-2,5-双(三甲基甲硅烷基)吡咯烷的单电子氧化双甲硅烷基化反应制得的(12 )。10与反式-3-(6-氯-3-吡啶基)-2-丙酸乙酯(22a)的环加成反应得到26,其中6-氯-3-吡啶基部分是内向的。脱羧,然后脱苄基,得到非天然差向异构体30,为1。所需的环加合物33是利用顺式-乙基-(6-氯-3-吡啶基)-2立体选择性地获得的,其中6-氯-3-吡啶基部分是外向取向的。 -丙酸酯(22b)为亲极性的。通过使用KO(t)()Bu的差向异构反应也将30转化为1。一种替代方法,涉及通过将10与丙酸乙酯环加成,将6-氯-3-碘吡啶(37)共轭加成到36,也建议用于1的立体选择性合成。通过这种策略,使用适当的双亲性亲核试剂合成了许多取代的表巴替丁(38、39、40、4
    DOI:
    10.1021/jo971728+
  • 作为产物:
    描述:
    2-氯-5-碘吡啶三氟乙酸 作用下, 生成 epibatidine
    参考文献:
    名称:
    Syntheses and biological properties of cysteine-Reactive epibatidine derivatives
    摘要:
    The synthesis of epibatidine derivatives modified at the 2-position of the pyridine or pyrimidine rings by reactive functions are described for potential irreversible site-directed coupling reactions on cysteine mutants of neuronal nicotinic acetylcholine receptors. An improved synthesis of the 7-azabicyclo[2,2,1]hepta-2,5-diene key intermediate has been developed to allow reproducible syntheses of the epibatidine derivatives. Binding tests and electrophysiological experiments allowed to select the 2-substituted alpha-chloroacetamido 13 and the chloropyrimidine derivative 11 as potential site-directed probes for the epibatidine binding site. (C) 2003 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(03)00092-1
点击查看最新优质反应信息

文献信息

  • Novel Bicyclic Pyridinones
    申请人:Pettersson Martin Youngjin
    公开号:US20120252758A1
    公开(公告)日:2012-10-04
    Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    所述化合物及其药用可接受的盐被披露,其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
  • [EN] 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS<br/>[FR] LIGANDS 6,7,8,9-TÉTRAHYDRO-5H-PYRIDO[2,3-D]AZÉPINE DU RÉCEPTEUR D3 DE LA DOPAMINE
    申请人:PFIZER
    公开号:WO2017122116A1
    公开(公告)日:2017-07-20
    The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
    本发明提供了Formula (I)的化合物及其药学上可接受的盐,其中变量R1、R2、R3、R4、R5、a和A如本文所定义;制备方法;制备中使用的中间体;以及含有这种化合物或盐的组合物,以及它们用于治疗D3介导的(或与D3相关的)疾病,包括物质成瘾、物质滥用、精神分裂症(例如其认知症状)、认知障碍(例如与精神分裂症、阿尔茨海默病或帕金森病相关的认知障碍)、帕金森病、狂躁症、焦虑、冲动控制障碍、性功能障碍和抑郁症等疾病的用途。
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    申请人:PFIZER INC.
    公开号:US20180208607A1
    公开(公告)日:2018-07-26
    The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    本发明在一定程度上提供了Formula I的化合物: 及其药用盐;制备方法;制备中使用的中间体;以及含有这些化合物或盐的组合物,以及它们用于治疗MAGL介导的疾病和紊乱,包括但不限于疼痛、炎症性紊乱、抑郁症、焦虑症、阿尔茨海默病、代谢紊乱、中风或癌症。
  • AMINO-HETEROCYCLIC COMPOUNDS
    申请人:Claffey Michelle M.
    公开号:US20100190771A1
    公开(公告)日:2010-07-29
    The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
    这项发明提供了式(I)中的PDE9抑制化合物,以及其药学上可接受的盐,其中R1、R2、R3、A和n的定义如本文所述。还提供了含有式I中化合物的药物组合物,并且提供了在治疗神经退行性和认知障碍疾病,如阿尔茨海默病和精神分裂症中的用途。
  • (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING
    申请人:IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    公开号:US20180139961A1
    公开(公告)日:2018-05-24
    (S)-5-ethynyl-anabasine and derivatives thereof; composition comprising same and a carrier; methods of treating an animal; method of protecting a plant from a pest; and methods of making compound and derivatives.
    (S)-5-乙炔基-阿那巴因及其衍生物;包含同样和载体的组合物;治疗动物的方法;保护植物免受害虫侵害的方法;以及制备化合物和衍生物的方法。
查看更多

同类化合物

2-(2'-氟-5'-吡啶基)-7-氮杂双环(2.2.1)庚烷 (±)-三色素蛙素 (1S,4R,6S)-6-(6-氯吡啶-3-基)-7-氮杂双环[2.2.1]庚烷 (1R,2R,4S)-2-(6-甲氧基吡啶-3-基)-7-氮杂双环[2.2.1]庚烷 2-fluoro-3-(2'-amino-4'-pyridinyl)deschlorocpibatidine 7-tert-butoxycarbonyl-2-exo-[2'-amino-3'-(pyridin-4-yl)-5'-pyridinyl]-7-azabicyelo[2.2.1]heptane (+/-)-N-Boc-epibatidine 7-carbethoxy-2β-(2-chloro-5-pyridinyl)-3α-carbomethoxy-7-azabicyclo<2.2.1>heptane 7-tert-butoxycarbonyl-2-exo-(2’-fluoro-3‘-(4-benzenesulfonamide)-5‘-pyridinyl)-7-azabicyclo[2.2.1]heptane 7-tert-butoxycarbonyl-2-exo-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one 7-tert-butoxycarbonyl-2-endo-(2-chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptan-3-one Tert-butyl 2-(6-amino-5-bromopyridin-3-yl)-7-azabicyclo[2.2.1]heptane-7-carboxylate (+/-)-epibatidine dihydrochloride (+)-Epibatidine dihydrochloride 7-carbomethoxy-2-(2-chloro-5-pyridyl)-7-aza-bicyclo[2.2.1]heptane (1R,2R,4S)-2-(6-Methoxy-pyridin-3-yl)-7-aza-bicyclo[2.2.1]heptane-7-carboxylic acid tert-butyl ester 2-(6-Chloro-5-phenyl-pyridin-3-yl)-7-aza-bicyclo[2.2.1]heptane (2S)-2-(6-Chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane Dtxcid1028865 4-((1R,2R,4S)-5-7-Aza-bicyclo[2.2.1]hept-2-yl-2-fluoro-pyridin-3-yl)-benzonitrile [(1R,2R,3S,4S)-7-Benzyl-3-(6-chloro-pyridin-3-yl)-7-aza-bicyclo[2.2.1]hept-2-yl]-((1S,5R,7R)-10,10-dimethyl-3,3-dioxo-3λ6-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-yl)-methanone (-)-epibatidine exo-2-(2'-fluoro-5'-pyridyl)-7-azabicyclo<2.2.1>heptane (1S,2S,4S)-2-(6-fluoropyridin-3-yl)-7-azabicyclo[2.2.1]heptane (1S,2R,4S)-2-(6-fluoropyridin-3-yl)-7-azabicyclo[2.2.1]heptane (+/-)-Epibatidine (1S,4R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane 2-(6-Bromopyridin-3-yl)-7-methyl-7-azabicyclo[2.2.1]heptane 2-(6-Chloro-2-methylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane;hydrochloride 6'-Methylepibatidine 2-(6-(18F)fluoranyl-5-phenylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane (1S,2R,4S)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane (1S,2R,4R)-2-(6-fluoropyridin-3-yl)-7-azabicyclo[2.2.1]heptane (1S,2S,4R)-2-(6-fluoropyridin-3-yl)-7-azabicyclo[2.2.1]heptane 2-(6-chloropyridin-3-yl)-7-(111C)methyl-7-azabicyclo[2.2.1]heptane (2R)-2-(6-(18F)fluoranylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane (-)-Epibatidine dihydrochloride 5-(7-Azabicyclo[2.2.1]heptan-2-yl)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one 3-(6-Chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptan-2-one 5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine;(1S,2S,4R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane 2-(6-(18F)fluoranylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane 2-(6-(125I)iodanylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane 2-(6-(123I)iodanylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane (3R,4S)-3-(6-chloro-3-pyridyl)-7-azabicyclo[2.2.1]heptane epibatidine